CLDX (Celldex Therapeutics) Ending Cash Position: $35.73 Mil (As of Mar. 2026)


CLDX Celldex Therapeutics Inc CLDX
57 GF Score
Price $39.11
GF Value $7.38
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Celldex Therapeutics Ending Cash Position?

Celldex Therapeutics CLDX +0.36% 57 Ending Cash Position is $35.73 Mil as of Mar. 2026. GuruFocus rates CLDX with a GF Score™ of 57/100 and a GF Value™ of $7.38 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Celldex Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was $35.73 Mil.

Celldex Therapeutics's quarterly Ending Cash Position declined from Sep. 2025 ($36.04 Mil) to Dec. 2025 ($28.87 Mil) but then increased from Dec. 2025 ($28.87 Mil) to Mar. 2026 ($35.73 Mil).

Celldex Therapeutics's annual Ending Cash Position declined from Dec. 2023 ($34.81 Mil) to Dec. 2024 ($28.36 Mil) but then increased from Dec. 2024 ($28.36 Mil) to Dec. 2025 ($28.87 Mil).

Celldex Therapeutics Ending Cash Position Related Terms

Celldex Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Celldex Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celldex Therapeutics Ending Cash Position Chart

Celldex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.14 29.43 34.81 28.36 28.87

Celldex Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.14 23.04 36.04 28.87 35.73
CLDX
57GF Score
Celldex Therapeutics Inc CLDX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celldex Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Celldex Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=28.356+0.51500000000001
=28.87

Celldex Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=28.871+6.858
=35.73

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $35.73 Mil mean?
Celldex Therapeutics (CLDX) has a Ending Cash Position of $35.73 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Celldex Therapeutics and its competitors.
Is Celldex Therapeutics' Ending Cash Position too high?
Celldex Therapeutics' current Ending Cash Position is $35.73 Mil. Overall, Celldex Therapeutics has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celldex Therapeutics' Ending Cash Position compare to TARS and KLRA?
Celldex Therapeutics' Ending Cash Position of $35.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Celldex Therapeutics and its competitors. Celldex Therapeutics's current Ending Cash Position is $35.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celldex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Celldex Therapeutics (CLDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.38, compared to a current price of $39.11 — trading 429.9% above its estimated fair value. The current Ending Cash Position is $35.73 Mil. Celldex Therapeutics' overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Celldex Therapeutics (CLDX), the current Ending Cash Position is $35.73 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celldex Therapeutics (CLDX) Overvalued in 2026?

Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued. The current stock price of $39.11 is trading 429.9% above its estimated GF Value™ of $7.38. GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.

Key valuation signals for CLDX:

  • Ending Cash Position: $35.73 Mil
  • GF Value™: $7.38 vs. price of $39.11 (429.9% above fair value)
  • GF Score™: 57/100 with 8 warning signs

No single metric tells the full story. See the CLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celldex Therapeutics Business Description

Other Exchanges TCE2:Germany
Address 53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
57GF Score

Get the complete analysis for CLDX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$39.11
Price
$7.38
GF Value